EFPIA contribution to DG Trade Consultation on “A renewed trade policy for a stronger Europe”
With COVID-19 impacting people across the globe, and inescapably re-shaping the world economy, the innovative pharmaceutical industry believes that a clear and forward-looking EU trade agenda is needed.
EFPIA contribution to DG Trade Consultation on “A renewed trade policy for a stronger Europe”
With COVID-19 impacting people across the globe, and inescapably re-shaping the world economy, the innovative pharmaceutical industry believes that a clear and forward-looking EU trade agenda is needed. This entails mobilising all resources to support the recovery of the EU economy, including ensuring that it remains open to the world. The EU is one of the few strong global players that stands for a rules-based global trading system and can take a global leadership role to promote this.
The innovative pharmaceutical industry is one of Europe’s core industries, contributing strongly to economic and social policy objectives, European values, as well as being at the forefront of combating the COVID-19 pandemic.
In this contribution EFPIA highlights the opportunities provided by the EU’s renewed trade strategy to support and strengthen its industry vis-à-vis global competitors.
The innovative pharmaceutical industry is one of Europe’s core industries, contributing strongly to economic and social policy objectives, European values, as well as being at the forefront of combating the COVID-19 pandemic.
In this contribution EFPIA highlights the opportunities provided by the EU’s renewed trade strategy to support and strengthen its industry vis-à-vis global competitors.